Bradmer Pharmaceuticals Completes Substantial Issuer Bid

September 08, 2009

Bradmer Pharmaceuticals Inc. (TSX:BMR) purchased for cancellation an aggregate of 7,461,588 common shares pursuant to a substantial issuer bid. The substantial issuer bid was completed pursuant to, and on the terms and conditions described in, the Offer to Purchase and Issuer Bid Circular of Bradmer dated July 21, 2009.

Wildeboer Dellelce LLP acted for Bradmer in connection with the issuer bid with a team that included Perry Dellelce, James Brown and Joanne Sanci (corporate/securities) and Kevin Fritz (tax).